Fred Hutchinson Cancer Research Center — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Affini-Taffinittx.com in 𝕏Mar 2022 · $175M

Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.

BiotechHealthtechLongevity

Co-investorsAgent Capital Olive Tree Capital Service Provider Capital Humboldt Leaps by Bayer Vida Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.